Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hyundai Motor (005380) – Notice of Holding Overseas Non-Deal Roadshow (NDR) for Foreign Institutional Investors

Posted on April 29, 2026July 23, 2026 By K-STOCK Editor No Comments on [Disclosure] Hyundai Motor (005380) – Notice of Holding Overseas Non-Deal Roadshow (NDR) for Foreign Institutional Investors

Fact Source: Financial Supervisory Service DART / 2026-04-29

Disclosure Type: Notice of Holding Investor Relations (IR)

💡 3-Second Summary

Hyundai Motor will hold an overseas Non-Deal Roadshow (NDR) from May 4 to June 5, 2026, across Europe, the U.S., and Asia, to present its Q1 2026 earnings results to major foreign institutional investors.

📊 1. [Key Disclosure Content & Summary of Figures]

  • Event Period & Region (Local Time):
    • Europe: May 4, 2026 – May 8, 2026 (Start Time: May 4, 2026 at 09:00)
    • U.S.: May 11, 2026 – May 15, 2026
    • Asia: May 25, 2026 – June 5, 2026
  • Location: Europe / U.S. / Asia
  • Target Audience: Major foreign institutional investors
  • Purpose: Conducting an overseas Non-Deal Roadshow (NDR)
  • Format: Investor meetings (One-on-One and small group)
  • Sponsoring Institutions: Korea Investment & Securities / UBS
  • Key Topics: Q1 2026 financial results and general investor areas of interest
  • IR Material Publication: Scheduled for April 29, 2026 (on the official company website)
  • Board Resolution Date: April 29, 2026

📈 2. [Expert Perspective: What This Filing Means for Investors]

This filing serves as a routine schedule notification regarding Hyundai Motor’s overseas Non-Deal Roadshow (NDR) sponsored by Korea Investment & Securities and UBS. Financial figures and specific performance data are not directly contained within this filing text.

The meetings are structured as One-on-One and small group sessions for foreign institutional investors, centered on the Q1 2026 earnings results. Official IR materials are scheduled to be published on the company website on April 29, allowing investors to review the factual metrics disclosed.

📝 Editor’s Comment (by K-STOCK Editor)

This announcement outlines an overseas NDR schedule covering Europe, the U.S., and Asia to engage directly with foreign institutional investors. The filing identifies the Q1 2026 earnings presentation and general investor interest topics as primary agenda items, without providing standalone numerical targets within the filing document itself.

Investors can review the official IR presentation materials scheduled for release on Hyundai Motor’s website on April 29, 2026, to examine the factual figures and earnings disclosures provided for these sessions.

📢 Disclaimer & Source Notice

Source: This content was newly generated and structured based on official submission data from the Financial Supervisory Service DART.

Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Automotive

Post navigation

Previous Post: [Disclosure] Samsung Electro-Mechanics Pref (009150) Hit with Investment Caution Following Near 100% Surge Monopolized by Foreign Accounts
Next Post: [Disclosure] Wonik IPS (240810) to Unveil Q1 Report Card on May 8… Official ‘Preliminary Earnings Schedule’ Announced

Related Posts

[Disclosure] Hanwha Aerospace (012450) Subsidiary Files Amendment Revising Acquisition Value to KRW 870.5B for Singapore’s Dyna-Mac Disclosures
[Disclosure] Celltrion (068270) Announces Future Plant Investment Plan of Up to KRW 700B for U.S. Facility Expansion to Respond to U.S. Drug Tariffs Disclosures
[Disclosure] Samsung Biologics(207940) Expands Merck Subsidiary CMO Contract by KRW 154.6B—Total Value Rises to KRW 247.3B Disclosures
[Disclosure] Celltrion 068270 Signs Joint R&D Agreement with Portrai for Spatial Transcriptomics-Based Antibody Discovery Valued up to KRW 125.9B Disclosures
[Disclosure] Alteogen (196170) Reports FY2025 Operating Profit of KRW 106.9B, Surging 320.8% YoY Disclosures
[Disclosure] SK Hynix (000660) Concludes Annual General Meeting: Confirms Record-Breaking 23.4 Trillion KRW Operating Profit and Approves Re-election of CEO Kwak Noh-jung Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme